^
Association details:
Biomarker:Chr t(8;21)(q22;q22) + RUNX1-RUNX1T1 fusion + KIT exon 17 mutation + CSF3R mutation
Cancer:Acute Myelogenous Leukemia
Regimen:IA (cytarabine + idarubicin hydrochloride)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C4 – Case Studies
Title:

Combination of Venetoclax and Midostaurin Efficiently Suppressed Relapsed t(8;21)Acute Myeloid Leukemia With Mutant KIT After Failure of Venetoclax Plus Azacitidine Treatment

Published date:
02/08/2022
Excerpt:
Case 1 is a 33-year-old female diagnosed with AML. Her karyotype was 45, X, -X, t(8;21)(q22;q22) (8)/46, XX, idem (2), AML1-ETO was 39700 copies/10000 abl copies (AML1-ETO transcripts were normalized to 104 abl copies), and KIT exon 17 and CSF3R mutations were detected. She was initially treated with a standard “3+7” regimen with idarubicin and cytarabine (IA) as induction with complete remission (CR) followed by four cycles of high-dose cytarabine (HiDAC) consolidation. However, 2 months after the last consolidation, the disease relapsed, and she failed to achieve CR again...
Secondary therapy:
cytarabine
DOI:
https://doi.org/10.3389/fonc.2022.841276